Welcome to our dedicated page for Apollomics SEC filings (Ticker: APLM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. filings document the regulatory record of a foreign private issuer developing oncology therapies. Its Form 6-K reports furnish financial-results releases, clinical-development updates for vebreltinib (APL-101), material agreements and license matters, related-party convertible-note financing, collaboration updates, and operational-continuity disclosures.
The filing record also covers governance and control procedures, including director appointments and committee composition, auditor changes, registration-statement incorporation, and litigation-related disclosures. These filings place Apollomics' oncology pipeline, capital structure, public-company governance and risk matters into formal SEC-reporting categories.
Apollomics Inc. (APLM) director Huang Ya-Chi reported the vesting and settlement of 500 Restricted Stock Units, each representing a contingent right to receive one Class A Ordinary Share. On August 17, 2026, these RSUs were exercised into 500 Class A Ordinary Shares at a reported price of $0.00 per share, increasing the director’s direct holdings to 1,500 Class A Ordinary Shares. Footnotes state the RSU award vests in four equal 500-share tranches on February 17, May 17, August 17, and November 17, 2026, with this transaction reflecting the August vesting.
Apollomics Inc. (APLM), a Cayman Islands corporation in the biotechnology sector, filed a Form D for a private exempt equity offering under Regulation D Rule 506(b). This is a new notice, with the first sale reported on August 14, 2026.
The company reports a total amount sold of $10,000,000 of Class A common shares, with $0 remaining to be sold, indicating the offering amount has been fully placed. Reported finders’ fees are $0. Apollomics declined to disclose its revenue or net asset size range. The notice is signed by Chief Financial Officer Peter Lin on behalf of the issuer.
Apollomics Inc. insider Yi-Kuei Chen, its Chief Operating Officer and director, reported an indirect purchase of 20,000 Class A ordinary shares of APLM on August 14, 2026 at $15.00 per share, acquired through a private placement transaction by Maxpro Investment Co., Ltd. Following this acquisition, indirect holdings through Maxpro Investment Co., Ltd. are reported as 121,248 shares, and a separate direct holding position of 15,000 shares is reported. The filing notes that Chen is a board member of Maxpro Investment Co., Ltd. and co-founder and managing director of Maxpro Ventures Ltd., and disclaims beneficial ownership of the Maxpro-held securities except to the extent of his pecuniary interest.
Apollomics Inc. executive Peter Kuan-How Lin, the Chief Financial Officer, purchased 26,667 Class A Ordinary Shares of APLM on August 14, 2026 at $15.00 per share. The shares were acquired pursuant to a private placement transaction referenced in a Form 6-K filed on August 12, 2026. Following this transaction, Lin directly holds 48,979 Class A Ordinary Shares.
Apollomics Inc. reported that Chief Executive Officer Hung-Wen Chen purchased a total of 536,667 Class A ordinary shares on August 14, 2026. The purchases, described as acquired pursuant to a private placement, included 166,667 shares at $12.00 per share and 103,333 shares at $15.00 per share held directly, and 266,667 shares at $15.00 per share held indirectly through King Regent Management Limited. Following the transaction, King Regent Management Limited held 1,029,695 shares, over which Mr. Chen has voting and dispositive power while disclaiming beneficial ownership beyond his pecuniary interest.
Apollomics Inc. reported that its Chairman and Chief Executive Officer, Hung‑Wen (Howard) Chen, together with his wholly owned vehicle King Regent Management Limited, completed a PIPE and note conversion on August 14, 2026. Mr. Chen and King Regent acquired an aggregate of 370,000 Class A ordinary shares for $5,550,005.00 in cash and through conversion of a convertible promissory note.
Following these transactions and recent RSU vesting, Mr. Chen beneficially owns 1,453,029 Class A shares, or 49.76% of the outstanding Class A shares, including 1,029,695 shares held through King Regent. The ownership percentage is based on 2,919,962 shares deemed outstanding under Rule 13d‑3(d)(1).
Apollomics Inc. disclosed an update on the holdings of investor Yi‑Kuei (Alex) Chen. An affiliated entity, Maxpro Investment Co., Ltd., entered into a Subscription Agreement on August 7, 2026 to purchase 20,000 Class A shares at $15.00 per share, for an aggregate purchase price of $300,000, in a private placement that closed on August 14, 2026.
Following this transaction, Mr. Chen beneficially owns 145,171 Class A shares, including shares held directly, RSUs vesting within 60 days, and warrants held by Maxpro, representing approximately 4.97% of the company’s Class A shares deemed outstanding for reporting purposes. Because the total number of outstanding Class A shares increased after the private placement, Mr. Chen ceased to be the beneficial owner of more than five percent of the class on August 14, 2026. The newly issued shares are restricted securities subject to transfer limitations under the Subscription Agreement.
Apollomics Inc. entered into definitive subscription agreements for a private placement of up to 700,001 Class A ordinary shares, for aggregate gross consideration of approximately $10.0 million, with accredited investors including certain executive officers, directors, and unaffiliated investors. The transaction is expected to close on or about August 14, 2026, subject to customary conditions.
The shares will be issued in unregistered transactions relying on Section 4(a)(2) and/or Rule 506 of Regulation D, and will be restricted securities subject to Rule 144 holding periods. Because related parties are participating, the subscriptions were treated as related-party transactions under Nasdaq rules and were reviewed by the independent Audit Committee and approved by the Board, with interested directors abstaining. No placement agents or underwriters are involved, and no fees or commissions are payable. Apollomics plans to use the net cash proceeds for clinical development, working capital, and general corporate purposes.
Apollomics Inc. director Yen Hung Hsien reported initial beneficial ownership of 500 restricted stock units linked to Class A Ordinary Shares. The RSUs were granted on July 20, 2026 and will vest on September 15, 2026, each converting into one share, subject to continued employment. The report is connected to the Holding Foreign Insiders Accountable Act.
Apollomics Inc. reported changes to its Board of Directors effective July 20, 2026. Directors Yi-An Chu and Dr. Chen-Huan (Jack) Jan resigned, and the company states these resignations were not related to any disagreement. The Board appointed Hung-Hsien Yen as a Class I director to fill the vacancy. He will also serve on the Audit Committee and as Chairman of the Nominating and Corporate Governance Committee.
Following these changes, the Board has six members, including four independent directors. Hung-Hsien Yen brings over 25 years of experience in private equity and direct investments and currently chairs SINO SUN CAPITAL INVESTMENT CO., LTD. His compensation includes 500 restricted stock units vesting on September 15, 2026, an annual cash retainer of $24,000, plus $5,000 for Audit Committee service and $10,000 for chairing the Nominating and Corporate Governance Committee. This information is incorporated by reference into Apollomics’ Form S-8 and Form F-3 registration statements.